韩国慢性乙型肝炎患者长期替诺福韦单药治疗的临床疗效。

StephenW

Clin Chim Acta. 2017 Jul 4. pii: S0009-8981(17)30245-0. doi: 10.1016/j.cca.2017.06.019. [Epub ahead of print]
Clinical response to long-term tenofovir monotherapy in Korean chronic hepatitis B patients.Yoo EH1, Cho HJ2.
Author information
1Department of Laboratory Medicine, Konyang University School of Medicine, Daejeon, Republic of Korea.2Department of Laboratory Medicine, Konyang University School of Medicine, Daejeon, Republic of Korea. Electronic address: [email protected].

AbstractBACKGROUND: Tenofovir disoproxil fumarate (TDF) is a potent nucleotide analogue recommended as first-line monotherapy for chronic hepatitis B (CHB). We investigated the clinical response to TDF monotherapy in Korean CHB patients.
METHODS: A total of 90 CHB patients [55 hepatitis B e antigen (HBeAg)-positive and 35 HBeAg-negative] who received TDF monotherapy for >2year, were enrolled. Quantitative hepatitis B surface antigen (qHBsAg) levels, serum alanine aminotransferase (ALT), HBeAg, anti-HBe and HBV DNA levels were measured during treatment. Virologic response (VR) was defined as undetectable HBV DNA level.
RESULTS: The cumulative incidences of complete virologic response (CVR) were 75.6% and 89.9% at months 12 and 24, respectively. The cumulative CVR rates were significantly higher in HBeAg-negative than HBeAg-positive group (P<0.001). HBeAg loss/seroconversion was observed in 21 (38.2%) out of 55 HBeAg-positive patients. One HBeAg-positive and 1 HBeAg-negative patients (2.2%) achieved HBsAg loss at months 6 and 8 of TDF therapy, respectively. Baseline HBV DNA level and qHBsAg were significant predictive factors for a CVR (P=0.001 and P<0.001, respectively).
CONCLUSIONS: Virologic, serologic, biochemical responses were achieved in both HBeAg-positive and HBeAg-negative patients under 24-month TDF therapy. Monitoring using baseline HBV DNA and qHBsAg levels would be helpful to predict CVR.

Copyright © 2017. Published by Elsevier B.V.

KEYWORDS: Chronic hepatitis B; Complete virologic response; HBV DNA; Quantitative hepatitis B surface antigen; Tenofovir

PMID:28687350DOI:10.1016/j.cca.2017.06.019

StephenW

Clin Chim Acta。 2017年7月4日。pii：S0009-8981（17）30245-0。 Doi：10.1016 / j.cca.2017.06.019。 [提前印刷]
韩国慢性乙型肝炎患者长期替诺福韦单药治疗的临床疗效。
Yoo EH1，Cho HJ2。
作者信息

1
韩国大田科ang大学医学院实验医学系。
2
韩国大田科ang大学医学院实验医学系。电子地址：[email protected]。

抽象
背景：

替诺福韦地索他芬富马酸（TDF）是推荐用作慢性乙型肝炎（CHB）一线单药治疗的强效核苷酸类似物。关于韩国​​CHB患者对TDF单药治疗的临床反应。
尿：

入选了TDF单药治疗≥20岁的90例CHB患者[HBaAg]阳性和35例HBeAg阴性患者。治疗期间测量乙型肝炎表面抗原（qHBsAg）水平，血清丙氨酸氨基转移酶（ALT），HBeAg，抗HBe和HBV DNA水平。病毒学反应（VR）被定义为不可检测的HBV DNA水平。
结果：

病毒学应答（CVR）的累积发生率分别为12和24，分别为75.6％和89.9％。 HBeAg阴性的累积CVR率显着高于HBeAg阳性组（P <0.001）。 HBeAg损失/血清转换HBeAg阳性和1例HBeAg阴性患者（2.2％）分别在TDF治疗第6和8个月时达到HBsAg损失。基线HBV DNA水平和qHBsAg是CVR的显着预测因子（分别为P = 0.001和P <0.001）。
结论：

在24个月的TDF治疗下，HBeAg阳性和HBeAg阴性患者均达到病毒学，血清学，生化反应。使用基线HBV DNA和qHBsAg水平进行监测有助于预测CVR。

版权所有©2017. Elsevier B.V.发行。
关键词：

慢性乙型肝炎完成病毒学应答HBV DNA;定量乙肝表面抗原;替诺福韦

结论：
28687350
DOI：
10.1016 / j.cca.2017.06.019

祈福2014

长期用替诺到底什么结果？

StephenW

回复 祈福2014 的帖子

两年的疗效很好.

antiHBVren

长期用，也有转阴的例子，但是和自然转阴没有什么明显优势，因而一般不说是TDF的功劳